FR2846667B1 - Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives - Google Patents
Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregativesInfo
- Publication number
- FR2846667B1 FR2846667B1 FR0213866A FR0213866A FR2846667B1 FR 2846667 B1 FR2846667 B1 FR 2846667B1 FR 0213866 A FR0213866 A FR 0213866A FR 0213866 A FR0213866 A FR 0213866A FR 2846667 B1 FR2846667 B1 FR 2846667B1
- Authority
- FR
- France
- Prior art keywords
- neuroagregative
- camelide
- diagnosis
- diseases
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0213866A FR2846667B1 (fr) | 2002-11-06 | 2002-11-06 | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
PCT/FR2003/003319 WO2004044204A2 (fr) | 2002-11-06 | 2003-11-06 | Fragments variables d'anticorps de camelides a chaine unique et leurs applications pour le diagnostic et le traitement de pathologies diverses. |
AU2003290158A AU2003290158A1 (en) | 2002-11-06 | 2003-11-06 | Variable fragments of single-chain camelide antibodies and uses thereof for diagnosing and treating various pathologies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0213866A FR2846667B1 (fr) | 2002-11-06 | 2002-11-06 | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2846667A1 FR2846667A1 (fr) | 2004-05-07 |
FR2846667B1 true FR2846667B1 (fr) | 2004-12-31 |
Family
ID=32104491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0213866A Expired - Fee Related FR2846667B1 (fr) | 2002-11-06 | 2002-11-06 | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003290158A1 (fr) |
FR (1) | FR2846667B1 (fr) |
WO (1) | WO2004044204A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
US7763249B2 (en) | 2004-04-27 | 2010-07-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid β peptide antibody and fragment of said antibody |
KR20070084170A (ko) * | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
WO2006066118A2 (fr) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Conditionnement contextuel des peurs pour predire l'efficacite immunotherapeutique |
US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
EP1934611A2 (fr) * | 2005-09-23 | 2008-06-25 | Academisch Ziekenhuis Leiden | Vhh pour le diagnostique, prevention et traitement des maladies dues a la formation d'agregats |
EP1785434A1 (fr) * | 2005-11-11 | 2007-05-16 | Ludwig-Maximilians-Universität München | Ciblage et suivi d'antigènes dans des cellules vivantes |
EP1976877B2 (fr) | 2005-11-30 | 2016-10-05 | AbbVie Inc. | Anticorps monoclonaux contre la protein beta-amyloide et utilisation de ceux-ci |
DK1954718T3 (en) | 2005-11-30 | 2014-12-15 | Abbvie Inc | Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2009017467A1 (fr) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Traitement de maladies amyloïdogéniques |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2486928A1 (fr) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Procédé pour le traitement des amyloses |
NZ579310A (en) | 2007-03-01 | 2012-03-30 | Probiodrug Ag | Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof |
EP1978035A1 (fr) * | 2007-04-05 | 2008-10-08 | Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung | Anticorps anti-amyloïdes et leur utilisation dans le diagnostic et la thérapie des maladies amyloïdes |
EP2142514B1 (fr) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2008666A1 (fr) | 2007-06-29 | 2008-12-31 | Institut Pasteur | Utilisation d'anticorps VHH pour la préparation de vecteurs de peptide pour fournir une substance d'intérêt et leurs applications |
EP2009445A1 (fr) * | 2007-06-29 | 2008-12-31 | Institut Pasteur | Utilisation d'anticorps à domaine simple de chaînes pour détecter une formule oligomérique d'un peptide amyloide bêta et ses applications |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
CA2730042A1 (fr) * | 2008-07-07 | 2010-01-14 | Athera Biotechnologies Ab | Nouveaux procedes therapeutiques et diagnostiques pour la maladie d'alzheimer |
EP2143735A1 (fr) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Domaines variables d'anticorps de camélidé à chaîne lourde dirigés contre les protéines acides fibrillaires gliales |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
CA2772488C (fr) | 2009-09-11 | 2018-04-17 | Probiodrug Ag | Derives heterocycliques en tant qu'inhibiteurs de glutaminyle cyclase |
PE20130527A1 (es) | 2010-03-03 | 2013-05-09 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta biparatopicos |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
CA2796339C (fr) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Proteines de liaison a la beta amyloide |
EP2560953B1 (fr) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibiteurs de glutaminyl cyclase |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2012042026A1 (fr) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Matières biologiques associées à c-met |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
EP4218933A1 (fr) | 2011-06-23 | 2023-08-02 | Ablynx NV | Proteines se liant a l'albumine serique |
US20180009888A9 (en) | 2011-06-23 | 2018-01-11 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US10112987B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
EP2873679A1 (fr) | 2013-11-13 | 2015-05-20 | F.Hoffmann-La Roche Ag | Anticorps à domaine unique de camélidés dirigés contre une substance amyloïde bêta et procédés pour produire des conjugués de ceux-ci |
EP2873680A1 (fr) | 2013-11-13 | 2015-05-20 | F.Hoffmann-La Roche Ag | Oligopeptide et procédés pour produire des conjugués de ceux-ci |
EP2899208A1 (fr) | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci |
BR122018009619B1 (pt) | 2014-05-16 | 2024-01-02 | Ablynx N.V | Domínios variáveis de imunoglobulina aperfeiçoados |
US11009511B2 (en) | 2014-05-16 | 2021-05-18 | Ablynx N.V. | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
WO2018111099A1 (fr) | 2016-12-12 | 2018-06-21 | Stichting Vumc | Biomarqueurs et traitements de l'angiopathie amyloïde cérébrale (aac) |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
EP0954978B1 (fr) * | 1998-03-12 | 2011-11-30 | VHsquared Limited | Produits contenant des levures ou des moisissures inactivées, ayant sur leur surface externe des anticorps actifs |
CN100434441C (zh) * | 1999-04-22 | 2008-11-19 | 荷兰联合利华有限公司 | 利用单价抗原-结合蛋白抑制病毒感染 |
CZ306683B6 (cs) * | 2000-02-24 | 2017-05-03 | Washington University | Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci |
GB0201611D0 (en) * | 2002-01-24 | 2002-03-13 | Grosveld Frank | Transgenic animal |
-
2002
- 2002-11-06 FR FR0213866A patent/FR2846667B1/fr not_active Expired - Fee Related
-
2003
- 2003-11-06 AU AU2003290158A patent/AU2003290158A1/en not_active Abandoned
- 2003-11-06 WO PCT/FR2003/003319 patent/WO2004044204A2/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2003290158A1 (en) | 2004-06-03 |
AU2003290158A8 (en) | 2004-06-03 |
WO2004044204A3 (fr) | 2004-09-10 |
WO2004044204A2 (fr) | 2004-05-27 |
FR2846667A1 (fr) | 2004-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2846667B1 (fr) | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives | |
AU2003299961A8 (en) | Capsule and method for treating or diagnosing conditions or diseases of the intestinal tract | |
FR13C0060I2 (fr) | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques | |
DE69528604T2 (de) | Medikamentenbehandlung erkrankter tiefliegender bereiche im inneren des körpers | |
IS5500A (is) | Lyfjablöndur til öftrunar og meðferðar mýlildi ogtengdum sjúkdómum | |
ATE252901T1 (de) | Arzneimittel zur behandlung von entzündlichen herzkrankheiten | |
DE60226702D1 (de) | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen | |
EP0808324A4 (fr) | Compositions destinees au traitement et au diagnostic de maladies cardio-vasculaires et techniques correspondantes | |
GB9925804D0 (en) | Biological materials and method useful in the diagnosis and treatment of diseases | |
DE60224163D1 (de) | Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen | |
IL132798A0 (en) | Monoesters of probucol for the treatment of cardiovascular and inflammatory disease | |
EP2322200A3 (fr) | Les compositions et les methodes pour le traitement de maladies liées immunisées | |
EP0959682A4 (fr) | Applications therapeutiques et de diagnostic de la laminine et de fragments de proteine derivee de la laminine | |
NO976094D0 (no) | Nye peptider avledet av humant varmesjokkprotein 60 for behandling av diabetes, fremgangsmåte og sett | |
PL339126A1 (en) | Demonstrative exhibit in the form of a living organism | |
FR2758143B1 (fr) | Inhibiteurs specifiques de la lipase pancreatique et leurs applications | |
DE50212280D1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
DZ3225A1 (fr) | Methode et compositions pour le traitement des maladies pulmonaires | |
WO2003055440A3 (fr) | Compositions et methodes de traitement de maladies d'origine immune | |
NO973193D0 (no) | Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer | |
DE60203878D1 (de) | Verfahren zur vorbeugung gegen und behandlung von unterleibsschmerzen und magen-darmerkrankungen | |
AU2002328212A1 (en) | Diagnosis and treatment of early pre-type 1 diabetes glial fibrillary acidic protein | |
AU2002364757A1 (en) | Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases | |
HUP0102116A2 (hu) | Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása | |
WO2004034974A3 (fr) | Anticorps anti-reg i$g(g) servant au traitement du cancer du colon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20060731 |